Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy

被引：1
|
作者：
Aydiner, Adnan [1 ]
Sari, Murat [1 ]
机构：
[1] Istanbul Univ, Inst Oncol, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21212
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
    Zhuang, Jingqi
    Yu, Yongfeng
    Li, Ziming
    Lu, Shun
    ONCOTARGET, 2017, 8 (32) : 53675 - 53683
  • [42] ASSOCIATIONS BETWEEN EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (EGFR-TKIS) AND VENOUS THROMBOEMBOLISM AMONG OLDER PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Byun, J. Y.
    Aiyeolemi, A. A.
    Park, C.
    VALUE IN HEALTH, 2023, 26 (06) : S45 - S45
  • [43] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    LUNG CANCER, 2021, 156 : S40 - S40
  • [44] Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
    Salimath, Shivalingaswamy
    Jayaraj, B. S.
    Mahesh, P. A.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [45] ANALYSIS OF THE EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER PATIENTS AFTER EGFR-TKIS TREATMENT
    Matsuo, Midori
    Nanae, Tomonaga
    Koichi, Izumikawa
    Hiroyuki, Yamaguchi
    Takaya, Ikeda
    Katsumi, Nakatomi
    Yoichi, Nakamura
    Kazuhiro, Tsukamoto
    Shigeru, Kohno
    RESPIROLOGY, 2010, 15 : 68 - 68
  • [46] Impact of Local Therapy on Disease Progression and Survival Outcomes in Oligometastatic Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC) Treated with First Line EGFR Tyrosine Kinase Inhibitors (Tkis)
    Soon, Y. Y.
    Lee, C. C.
    Koh, W. Y.
    Leong, C. N.
    Tey, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E152 - E152
  • [47] Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Zhang, Bo
    Xu, Jianlin
    Zhang, Xueyan
    Gu, Ping
    Wang, Huimin
    Wang, Shuyuan
    Qian, Jie
    Qiao, Rong
    Zhang, Yanwei
    Yang, Wenjia
    Qian, Fangfei
    Zhou, Yan
    Lu, Jun
    Zhang, Lele
    Han, Baohui
    LUNG CANCER, 2018, 117 : 27 - 31
  • [48] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Raimbourg, Judith
    Joalland, Marie-Pierre
    Cabart, Mathilde
    de Plater, Ludmilla
    Bouquet, Fanny
    Savina, Ariel
    Decaudin, Didier
    Bennouna, Jaafar
    Vallette, Francois M.
    Lalier, Lisenn
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
  • [49] Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report
    Spreafico, A.
    Grigorieva, J.
    Cattaneo, A.
    Belli, C.
    Tsypin, M.
    Roder, H.
    Giovannini, M.
    Alessio, M.
    Gregorc, V.
    Bachi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Complex epidermal growth factor receptor (EGFR) mutations and responses to tyrosine kinase inhibitors (TKIs) in advanced lung adenocarcinomas
    Zhang, B.
    Wang, S.
    Qian, J.
    Yang, W.
    Qian, F.
    Lu, J.
    Zhang, Y.
    Qiao, R.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S82 - S82
12345